Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
12 July 2023Website:
http://www.60degreespharma.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | 28 min agoDividend
Analysts recommendations
Institutional Ownership
SXTP Latest News
Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs. ARAKODA is the only new antimalarial in over a decade and is differentiated by a broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile.
60 Degrees Pharmaceuticals Inc. (SXTP) came out with a quarterly loss of $4.23 per share versus the Zacks Consensus Estimate of a loss of $3.96. This compares to loss of $16.81 per share a year ago.
Q2 2024 net product revenues doubled year-over-year to $125 thousand Sequential (quarter-over-quarter) net product revenue growth of 18.3% Gross profit increased from ($124 thousand) to $35 thousand, year-over-year WASHINGTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the second quarter of 2024, ended June 30, 2024. Financial Highlights: 110% net product revenue growth resulted from an increase in ARAKODA® pharmacy deliveries of 288%, from 331 boxes (Q2 2023) to 1,301 boxes (Q2 2024).
60 Degrees Pharmaceuticals (NASDAQ: SXTP ) stock is gaining on Monday after the specialty pharmaceutical company announced an agreement with the University of Kentucky. This agreement will have the University of Kentucky conducting a Phase IIb clinical trial of SJ733.
60 Degrees Pharma grants U of Kentucky a right of reference to ARAKODA® NDA for a Phase IIb trial combining SJ733 with tafenoquine to treat vivax malaria.
60 Degrees Pharma (NASDAQ: SXTP) announces a 1-for-12 reverse stock split, effective August 12, 2024 to meet Nasdaq's $1.00 minimum bid price requirement.
60 Degrees Pharmaceuticals secures a U.S. Army contract to support ARAKODA® packaging validation, with Q1 2024 sales up 515% year-over-year to $105.7K.
60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025
60 Degrees (NASDAQ: SXTP ) stock is on the rise Friday alongside heavy early morning trading of the specialty pharmaceutical company's shares. This has more than 12.5 million shares of SXTP stock being traded as of this writing.
WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced ethics approval of an open label, expanded access study of the ARAKODA® regimen of tafenoquine in combination with standard of care regimens in immunosuppressed patients with persistent/relapsing babesiosis. The goal of the study is to confirm the findings of an 80 percent babesiosis cure rate in humans observed in a similar population in an earlier case series of tafenoquine completed by Yale School of Public Health (YSPH) in April 2024 and published in the journal, Clinical Infectious Diseases.
What type of business is 60 Degrees Pharmaceuticals?
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
What sector is 60 Degrees Pharmaceuticals in?
60 Degrees Pharmaceuticals is in the Healthcare sector
What industry is 60 Degrees Pharmaceuticals in?
60 Degrees Pharmaceuticals is in the Biotechnology industry
What country is 60 Degrees Pharmaceuticals from?
60 Degrees Pharmaceuticals is headquartered in United States
When did 60 Degrees Pharmaceuticals go public?
60 Degrees Pharmaceuticals initial public offering (IPO) was on 12 July 2023
What is 60 Degrees Pharmaceuticals website?
https://www.60degreespharma.com
Is 60 Degrees Pharmaceuticals in the S&P 500?
No, 60 Degrees Pharmaceuticals is not included in the S&P 500 index
Is 60 Degrees Pharmaceuticals in the NASDAQ 100?
No, 60 Degrees Pharmaceuticals is not included in the NASDAQ 100 index
Is 60 Degrees Pharmaceuticals in the Dow Jones?
No, 60 Degrees Pharmaceuticals is not included in the Dow Jones index
When was 60 Degrees Pharmaceuticals the previous earnings report?
No data
When does 60 Degrees Pharmaceuticals earnings report?
Next earnings report date is not announced yet